News

On April 15, 2022, NCI’s Surveillance Research Program released the latest Surveillance, Epidemiology, and End Results (SEER) data based on November 2021 data submissions. As a cancer researcher or data scientist, discover how you can access these cancer statistics and data for your research and analysis.

Help the FDA’s National Center for Toxicological Research and the precisionFDA optimize data processing pipelines for identifying indels (i.e., insertions/deletions in a genome) in oncopanel sequencing datasets by participating in a sequencing data challenge. Pre-register for the “Indel Calling from Oncopanel Sequencing Data Challenge” before May 2, 2022! Selected participants will be publicly recognized and invited to contribute to a scientific manuscript and a “Top Performer Webinar” that will be open to the public.

IMPROVE focuses on improving deep learning models to predict the efficacy of cancer treatments. The research community, including data scientists and informaticists, is asked to respond to an RFI for creating protocols to evaluate model performance by April 15, 2022, at 5:00 p.m. ET. Additionally, they are encouraged to respond to an RFP for improving model comparison by May 9, 2022.

Investigators from NCI’s Center for Cancer Research developed a software package to perform high-throughput analysis of extracellular vesicles, which are particles a cell releases that can promote cell growth and survival. NCI is now seeking research co-development partners and/or licensees for this biomarker analysis software.

If you’re attending the 2022 American Association for Cancer Research Annual Meeting (either in person or virtual), don’t miss these data science sessions, poster presentations, and the NCI exhibit booth, where you can hear more about our programs and activities!

Do you work on a project funded by an active NIH grant? Is this project rooted in artificial intelligence, machine learning, and/or ethics components? Apply to this Notice of Special Interest by March 31, 2022.

Over the past several years, scientists have made exciting advances in the realm of artificial intelligence (AI) and its integration into the cancer imaging field. New AI tools could make cancer imaging faster, more accurate, and more informative. But are they ready for real-world implementation?

NCI has just launched the Molecular Characterization Initiative, fostering data sharing in childhood cancer research. This program offers tumor molecular characterization to children, adolescents, and young adults who have been diagnosed with central nervous system tumors and are being treated at hospitals affiliated with an NCI-supported clinical trials group, “Children’s Oncology Group.” The DNA and RNA in participants' tumors are analyzed through this voluntary, free program. Once data is available, cancer researchers will be able to access the data via the Cancer Research Data Commons.

Looking for canine urothelial carcinoma data? RNA sequencing and clinical data from a phase I/II trial, listed in the EACR’s top 10 publications, is available for analysis through NCI’s Integrated Canine Data Commons.

Have experience with data management, high performance computing, and/or machine learning/artificial intelligence? Are you a proven IT manager and leader? Become a Staff Scientist/Facility Head to direct and manage a shared Scientific Computing and Informatics Core within the National Institute on Drug Abuse, a sister institute of the National Cancer Institute.